Aquestive Therapeutics, Inc. (AQST)

What does Aquestive actually do?

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing proprietary drug delivery technologies, primarily transmucosal and dissolvable products. Rather than competing in the crowded landscape of traditional pills and injections, the company specializes in reformulating existing active pharmaceutical ingredients into novel delivery forms—dissolving tablets placed under the tongue, in the cheek, or delivered through other mucosal membranes. This approach can improve efficacy, speed of action, and patient compliance for conditions ranging from acute seizures to chronic pain.

Who uses these products?

The company’s marketed products target patients with epilepsy, opioid use disorder, and other serious conditions where rapid drug delivery or improved absorption matters. AQST’s most prominent asset is Libervant (diazepam), an FDA-approved dissolvable formulation for acute seizure clusters, which competes with traditional rectal and intramuscular diazepam delivery. Another product, Suboxone (buprenorphine/naloxone), leverages a dissolvable film format for opioid use disorder treatment—a significant market as addiction treatment expands. The company has also been involved in pain and psychiatric indications through partnered or acquired programs.

How does the business model work?

Aquestive primarily commercializes products through direct pharmaceutical sales and distribution partnerships. The company generates revenue by selling products to wholesalers, hospital systems, and pharmacy benefit managers, and it also pursues licensing or partnership arrangements for its technology platform with larger pharma firms. The economics depend heavily on whether products gain market share against established competitors and generic alternatives in each therapeutic area.

What are the main risks?

Like other specialty pharma firms, Aquestive faces intense competition from both branded incumbents and generics, regulatory pressures that can limit pricing flexibility, and the ever-present risk that a marketed product fails to achieve expected adoption. The transmucosal delivery space is somewhat niche, so the company’s success rests on a small portfolio of products that must perform commercially. Additionally, the company has historically carried significant debt and operating losses, which constrains financial flexibility and investment capacity.

Why does the company exist in this form?

Aquestive was founded to capitalize on proprietary formulation science—the insight that changing how drugs are delivered can create value even when the active ingredient is old or off-patent. By taking well-understood drugs and creating new intellectual property through delivery innovation, the company can secure periods of exclusivity and premium pricing before facing generic competition. This strategy is most viable when the improvement is genuinely meaningful to patients or providers (faster onset, better compliance, reduced side effects) rather than merely cosmetic.